Related Experiment Video
Updated: Jan 16, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers
Kosar Zolfaghari1, Mohammad Yazdi1,2, Shaghayegh Mohammadioun1
1Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Abstract:
Head and neck squamous cell carcinomas (HNSCCs) rank seventh among the most prevalent malignancies globally. The immune response in cancer conditions governs the course of the disease and clinical outlook. Interferons (IFNs) are a key part of the innate immune system and are essential in modulating the tumor microenvironment (TME). Additionally, IFNs could influence proliferation and affect differentiation, emigration, and death of cancer cells. The cGAS-stimulator of interferon genes (STING) signaling identifies cytosolic DNA and triggers an immune response. Aberrant induction of the cGAS-STING signaling may lead to excess and sustained release of type-I IFN, leading to imbalanced aggregation in various tissues or organs. It is noteworthy that STING signaling has shown a dual role, both promoting tumor resistance and antitumor immunity. Moreover, STING agonists have been investigated in recent studies; however, challenges such as toxicity should be addressed. IFNs have also been used as monotherapy or adjuvant treatment before chemotherapy to increase efficacy against HNSCC tumors. The present review briefly describes IFN signaling with a focus on the STING pathway, and discusses its role in modulating immunotherapy and chemotherapy effects in HNSCC.
Insights
Interferons (IFNs) and STING pathway signaling play crucial roles in head and neck squamous cell carcinomas (HNSCCs). Understanding their dual roles in immunity and cancer progression is key for effective treatment strategies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Head and neck squamous cell carcinomas (HNSCCs) are a significant global health concern.
- Immune responses critically influence cancer progression and patient outcomes.
- Interferons (IFNs) are vital innate immune components modulating the tumor microenvironment (TME) and cancer cell fate.
Purpose of the Study:
- To review Interferon (IFN) signaling, with a specific focus on the cGAS-stimulator of interferon genes (STING) pathway.
- To discuss the role of STING signaling in modulating immunotherapy and chemotherapy efficacy in HNSCC.
- To highlight the dual role of STING in tumor resistance and antitumor immunity.
Main Methods:
- Literature review of Interferon (IFN) signaling pathways.
- Focus on the cGAS-STING pathway's mechanism in cancer.
- Analysis of STING's role in modulating therapeutic responses in HNSCC.
Main Results:
- STING signaling identifies cytosolic DNA and initiates immune responses.
- Aberrant cGAS-STING activation can lead to excessive type-I IFN release and tissue imbalance.
- STING signaling exhibits a dual role, potentially promoting both tumor resistance and antitumor immunity.
Conclusions:
- IFNs and the STING pathway are critical in HNSCC pathogenesis and immune modulation.
- STING agonists show therapeutic potential but require careful toxicity management.
- Further understanding of STING's role can optimize immunotherapy and chemotherapy for HNSCC.
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Intracellular Signaling Affects Focal Adhesions
Some...

